Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Gyre Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$6.34M. For fiscal 2025 it was $1.01M. The highest annual figure on record is $138.30M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | – |
| FY2024 | Dec 31, 2024 | -$3.64M | -114.1% |
| FY2023 | Dec 31, 2023 | $25.89M | +142.5% |
| FY2022 | Dec 31, 2022 | $10.68M | – |
| FY2021 | Dec 31, 2021 | -$83.76M | – |
| FY2020 | Dec 31, 2020 | -$55.05M | – |
| FY2019 | Dec 31, 2019 | -$43.61M | – |
| FY2018 | Dec 31, 2018 | -$28.55M | – |
| FY2017 | Dec 31, 2017 | -$19.94M | – |
| FY2016 | Dec 31, 2016 | -$18.47M | – |
| FY2015 | Dec 31, 2015 | -$19.12M | – |
| FY2014 | Dec 31, 2014 | -$6.39M | – |
| FY2013 | Dec 31, 2013 | -$6.27M | – |
| FY2012 | Dec 31, 2012 | -$64.24M | – |
| FY2011 | Dec 31, 2011 | -$83.72M | -160.5% |
| FY2010 | Dec 31, 2010 | $138.30M | – |
| FY2009 | Dec 31, 2009 | -$24.27M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.98M | – |
| Q2 FY2026 | Jun 30, 2026 | -$16.73M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.18M | – |
| Q4 FY2025 | Dec 31, 2025 | $11.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.58M | -249.6% |
| Q2 FY2025 | Jun 30, 2025 | -$7.47M | – |
| Q1 FY2025 | Mar 31, 2025 | -$129.00K | -104.5% |
| Q4 FY2024 | Dec 31, 2024 | -$2.76M | -182.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.73M | -77.2% |
| Q2 FY2024 | Jun 30, 2024 | -$5.49M | -221.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.88M | -72.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.36M | -92.1% |
| Q3 FY2023 | Sep 30, 2023 | $7.58M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.53M | – |
| Q1 FY2023 | Mar 31, 2023 | $10.42M | – |
| Q4 FY2022 | Dec 31, 2022 | $42.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.79M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.09M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.47M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.96M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.01M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.41M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.11M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.32M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.93M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.40M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.29M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.98M | – |
See a number that looks wrong?